Ifosfamide-induced nephrotoxicity in oncological patients

Juan Eduardo Quiroz-Aldave; María Del Carmen Durand-Vásquez; Freddy Shanner Chávez-Vásquez; Alexandra Noelia Rodríguez-Angulo; Sonia Elizabeth Gonzáles-Saldaña; Carlos César Alcalde-Loyola; Julia Cristina Coronado-Arroyo; Francisca Elena Zavaleta-Gutiérrez; Luis Alberto Concepción-Urteaga; Juan Carlos Haro-Varas; Marcio José Concepción-Zavaleta

doi:10.1080/14737140.2023.2290196

Ifosfamide-induced nephrotoxicity in oncological patients

Juan Eduardo Quiroz-Aldave, María Del Carmen Durand-Vásquez, Freddy Shanner Chávez-Vásquez, Alexandra Noelia Rodríguez-Angulo, Sonia Elizabeth Gonzáles-Saldaña, Carlos César Alcalde-Loyola, Julia Cristina Coronado-Arroyo, Francisca Elena Zavaleta-Gutiérrez, Luis Alberto Concepción-Urteaga, Juan Carlos Haro-Varas, Marcio José Concepción-Zavaleta

Universidad Científica del Sur

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Introduction: Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage. Areas covered: A comprehensive review was conducted, including 100 articles from the Scielo, Scopus, and EMBASE databases. Ifosfamide-induced nephrotoxicity is attributed to its toxic metabolites, such as acrolein and chloroacetaldehyde, which cause mitochondrial damage and oxidative stress in renal tubular cells. Literature review found a 29-year average age with no gender predominance and a mortality of 13%. Currently, no fully effective strategy exists for preventing ifosfamide-induced nephrotoxicity; however, hydration, forced diuresis, and other interventions are employed to limit renal damage. Long-term renal function monitoring is essential for patients treated with ifosfamide. Expert opinion: Ifosfamide remains essential in neoplasm treatment, but nephrotoxicity, often compounded by coadministered drugs, poses diagnostic challenges. Preventive strategies are lacking, necessitating further research. Identifying timely risk factors can mitigate renal damage, and a multidisciplinary approach manages established nephrotoxicity. Emerging therapies may reduce ifosfamide induced nephrotoxicity.

Original language	English
Pages (from-to)	5-14
Number of pages	10
Journal	Expert Review of Anticancer Therapy
Volume	24
Issue number	1-2
DOIs	https://doi.org/10.1080/14737140.2023.2290196
State	Published - 2024

Keywords

Fanconi syndrome
Ifosfamide
drug-related side effects and adverse reactions
neoplasms
nephrogenic diabetes insipidus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/14737140.2023.2290196

Cite this

Quiroz-Aldave, J. E., Durand-Vásquez, M. D. C., Chávez-Vásquez, F. S., Rodríguez-Angulo, A. N., Gonzáles-Saldaña, S. E., Alcalde-Loyola, C. C., Coronado-Arroyo, J. C., Zavaleta-Gutiérrez, F. E., Concepción-Urteaga, L. A., Haro-Varas, J. C., & Concepción-Zavaleta, M. J. (2024). Ifosfamide-induced nephrotoxicity in oncological patients. Expert Review of Anticancer Therapy, 24(1-2), 5-14. https://doi.org/10.1080/14737140.2023.2290196

@article{1fd23f4d018c4cbab173b3d63818b5f6,

title = "Ifosfamide-induced nephrotoxicity in oncological patients",

abstract = "Introduction: Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage. Areas covered: A comprehensive review was conducted, including 100 articles from the Scielo, Scopus, and EMBASE databases. Ifosfamide-induced nephrotoxicity is attributed to its toxic metabolites, such as acrolein and chloroacetaldehyde, which cause mitochondrial damage and oxidative stress in renal tubular cells. Literature review found a 29-year average age with no gender predominance and a mortality of 13%. Currently, no fully effective strategy exists for preventing ifosfamide-induced nephrotoxicity; however, hydration, forced diuresis, and other interventions are employed to limit renal damage. Long-term renal function monitoring is essential for patients treated with ifosfamide. Expert opinion: Ifosfamide remains essential in neoplasm treatment, but nephrotoxicity, often compounded by coadministered drugs, poses diagnostic challenges. Preventive strategies are lacking, necessitating further research. Identifying timely risk factors can mitigate renal damage, and a multidisciplinary approach manages established nephrotoxicity. Emerging therapies may reduce ifosfamide induced nephrotoxicity.",

keywords = "Fanconi syndrome, Ifosfamide, drug-related side effects and adverse reactions, neoplasms, nephrogenic diabetes insipidus",

author = "Quiroz-Aldave, {Juan Eduardo} and Durand-V{\'a}squez, {Mar{\'i}a Del Carmen} and Ch{\'a}vez-V{\'a}squez, {Freddy Shanner} and Rodr{\'i}guez-Angulo, {Alexandra Noelia} and Gonz{\'a}les-Salda{\~n}a, {Sonia Elizabeth} and Alcalde-Loyola, {Carlos C{\'e}sar} and Coronado-Arroyo, {Julia Cristina} and Zavaleta-Guti{\'e}rrez, {Francisca Elena} and Concepci{\'o}n-Urteaga, {Luis Alberto} and Haro-Varas, {Juan Carlos} and Concepci{\'o}n-Zavaleta, {Marcio Jos{\'e}}",

note = "Publisher Copyright: {\textcopyright} 2023 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2024",

doi = "10.1080/14737140.2023.2290196",

language = "Ingl{\'e}s",

volume = "24",

pages = "5--14",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor and Francis Ltd.",

number = "1-2",

}

Quiroz-Aldave, JE, Durand-Vásquez, MDC, Chávez-Vásquez, FS, Rodríguez-Angulo, AN, Gonzáles-Saldaña, SE, Alcalde-Loyola, CC, Coronado-Arroyo, JC, Zavaleta-Gutiérrez, FE, Concepción-Urteaga, LA, Haro-Varas, JC & Concepción-Zavaleta, MJ 2024, 'Ifosfamide-induced nephrotoxicity in oncological patients', Expert Review of Anticancer Therapy, vol. 24, no. 1-2, pp. 5-14. https://doi.org/10.1080/14737140.2023.2290196

TY - JOUR

T1 - Ifosfamide-induced nephrotoxicity in oncological patients

AU - Quiroz-Aldave, Juan Eduardo

AU - Durand-Vásquez, María Del Carmen

AU - Chávez-Vásquez, Freddy Shanner

AU - Rodríguez-Angulo, Alexandra Noelia

AU - Gonzáles-Saldaña, Sonia Elizabeth

AU - Alcalde-Loyola, Carlos César

AU - Coronado-Arroyo, Julia Cristina

AU - Zavaleta-Gutiérrez, Francisca Elena

AU - Concepción-Urteaga, Luis Alberto

AU - Haro-Varas, Juan Carlos

AU - Concepción-Zavaleta, Marcio José

PY - 2024

Y1 - 2024

N2 - Introduction: Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage. Areas covered: A comprehensive review was conducted, including 100 articles from the Scielo, Scopus, and EMBASE databases. Ifosfamide-induced nephrotoxicity is attributed to its toxic metabolites, such as acrolein and chloroacetaldehyde, which cause mitochondrial damage and oxidative stress in renal tubular cells. Literature review found a 29-year average age with no gender predominance and a mortality of 13%. Currently, no fully effective strategy exists for preventing ifosfamide-induced nephrotoxicity; however, hydration, forced diuresis, and other interventions are employed to limit renal damage. Long-term renal function monitoring is essential for patients treated with ifosfamide. Expert opinion: Ifosfamide remains essential in neoplasm treatment, but nephrotoxicity, often compounded by coadministered drugs, poses diagnostic challenges. Preventive strategies are lacking, necessitating further research. Identifying timely risk factors can mitigate renal damage, and a multidisciplinary approach manages established nephrotoxicity. Emerging therapies may reduce ifosfamide induced nephrotoxicity.

AB - Introduction: Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage. Areas covered: A comprehensive review was conducted, including 100 articles from the Scielo, Scopus, and EMBASE databases. Ifosfamide-induced nephrotoxicity is attributed to its toxic metabolites, such as acrolein and chloroacetaldehyde, which cause mitochondrial damage and oxidative stress in renal tubular cells. Literature review found a 29-year average age with no gender predominance and a mortality of 13%. Currently, no fully effective strategy exists for preventing ifosfamide-induced nephrotoxicity; however, hydration, forced diuresis, and other interventions are employed to limit renal damage. Long-term renal function monitoring is essential for patients treated with ifosfamide. Expert opinion: Ifosfamide remains essential in neoplasm treatment, but nephrotoxicity, often compounded by coadministered drugs, poses diagnostic challenges. Preventive strategies are lacking, necessitating further research. Identifying timely risk factors can mitigate renal damage, and a multidisciplinary approach manages established nephrotoxicity. Emerging therapies may reduce ifosfamide induced nephrotoxicity.

KW - Fanconi syndrome

KW - Ifosfamide

KW - drug-related side effects and adverse reactions

KW - neoplasms

KW - nephrogenic diabetes insipidus

UR - http://www.scopus.com/inward/record.url?scp=85178397918&partnerID=8YFLogxK

U2 - 10.1080/14737140.2023.2290196

DO - 10.1080/14737140.2023.2290196

M3 - Artículo

C2 - 38031874

AN - SCOPUS:85178397918

SN - 1473-7140

VL - 24

SP - 5

EP - 14

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 1-2

ER -

Ifosfamide-induced nephrotoxicity in oncological patients

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this